Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Assoc. Prof Rose Mary Ferreira Lisboa da Silva,
Chagas disease is endemic to Latin America and efforts have been made to eradicate the triatomine insect in homes. However, world immigration and travel have caused the disease to go global and after a presentation of the disease, here we focus on syncope, as one of the manifestations of the chronic form.
According to the World Health Organisation, Chagas disease (American trypanosomiasis) represents the third largest tropical disease burden after 1) malaria: 40 million people infected in numerous tropical and subtropical countries and 2) schistosomiasis, also referred to as snail fever: 30 million infected in Asia, Africa, and South America. Approximately 10 million people are infected with Trypanosoma Cruzi, the etiological agent of Chagas disease. Cases are mostly in Latin America but others occur to other parts of the world as a result of migration, including in Europe, where expected prevalence of infected individuals is approximately 40,000. Approximately 90% of transmission of Chagas disease occurs through an insect of certain species of triatoma within the reduviidae family, of which the triatoma infectans is the main vector (Fig. 1). These insects can carry the protozoan Trypanosoma cruzi, the parasite isolated in 1909 by the Brazilian physician Carlos Chagas and are almost exclusively established inside human dwellings and/or peridomestic structures. Insects are the intermediate hosts of the disease. Nocturnal, the bugs live in cracks and crevices of rural clay or mud houses and take blood meals on humans and animals while they are sleeping. Also referred to as "kissing bugs" they bite usually near the mouth or eyes, and defecate after feeding, dropping infective trypomastigote forms, which penetrate through the hole of the bite or solution of continuity left by scratching, or even by active penetration of the mouth and mucous and eyes. The bugs are responsible for transmitting disease in 90% of cases. They get the disease from biting animals or humans, which are both the primary hosts in which the parasite reaches maturity. Trypanosoma cruzi have been found in 150 species of animals that are an immense reservoir for the disease and 10 million infected humans. Death resulting from Chagas disease occurred in an estimated 10,000 people in the year 2008. (1) Infection can also occur through blood transfusions, from mother to child via placenta, from ingestion of contaminated food and juices or from organ transplants. Globalisation has lead to increased migration of infected individuals to cities both within and outside Latin America, thus to non-endemic countries, mainly the United States, Alaska, Spain, Canada, Japan, Australia, France, Italy and the United Kingdom (2).
The acute phase of the disease lasts 4-8 weeks and is usually asymptomatic although a distinctive swelling of the eye, referred to as Ramona's sign that may develop at the beginning of the 1-2 week incubation period in the first days after the bite. Death, from myocarditis and/or meningoencephalitis occurs in less than 5% to 10% of symptomatic patients. The acute phase may also occur due to reactivation of disease in patients with immunosuppressive states and in patients undergoing organ transplantation. During the acute or reactivation phase, diagnosis can be made with a search the protozoan or to study the host immune response by serum antibodies. Standard treatment during the acute phase is benznidazole for a 60-90 day course, which tends to be better tolerated then nifurtimox. Nevertheless, both medications are expensive, have high risks of side effects, and cannot be used in pregnant women or those with renal or hepatic insufficiency. These anti-parasitic medications, if given early, can reduce the duration and severity of infection, but are only half effective in killing the organism itself. There is currently no approved treatment for chronic Chagas disease and there are currently no vaccines in use. Sixty to 70% of those infected will never develop the disease and most often do not know they have been infected. They are said to have the indeterminate form. However 30% of all those infected, between 10 to 30 years after an initial infection that was left untreated or was unresponsive to parasitic elimination, will develop a chronic form which attacking internal organs will take on, in 20% of cases, a cardiac form, with or without ventricular dysfunction and in 10% to 15% of cases, a digestive or cardiodigestive form (3,4). During this stage, diagnosis is made after a study of the patient's clinical findings, and likelihood of being infected, such as having lived or visited an endemic country. Diagnosis is can be made by testing with at least two different serologic tests. Typical manifestation of Chagas heart disease is dilated cardiomyopathy, congestive heart failure, arrhythmias, cardioembolism, and syncope. Here will focus on syncope.
Main causes for syncope in Chagasic disease are 1) neurological mechanism, 2) sinus node dysfunction, 3) atrioventricular block and 4) ventricular tachycardia.
Figure 1: A haematophagous insect, which can become a vector for Trypanosoma cruzi by biting an infected animal or person. The bugs usually live in palm trees and rock crevices, but some live in human dwellings, typically hiding during the day in the cracked walls of mud or mud-brick houses, and coming out at night to feed.
Figure 2: Twelve-lead electrocardiogram of a 69-year-old male patient with chronic Chagas disease, (before pacemaker implantation) with manifestations of syncope without prodrome, in orthostatism and no trauma, showing low atrial rhythm and AV block 2:1 and ventricular rate of 37 beats per minute. In CM5 lead, there is a period of second-degree atrioventricular block Mobitz I. Patient underwent implantation of dual chamber pacemaker, with remission of symptoms. Figure 2b: A tracing with a long derivation, (before pacemaker application). Figure 3: 12-lead electrocardiogram of 49-year-old male patient, with chronic Chagas disease, with symptoms of sudden palpitations and syncope, demonstrating sustained ventricular tachycardia with morphology of right bundle branch block, with periods of atrioventricular dissociation and ventricular rate of 230 beats per minute. The patient underwent successful defibrillation. By the echocardiogram, his ejection fraction of left ventricle was 0.47. He underwent implantation of a cardioverter-defibrillator. Figure 4: Intra-cardiac tracing recorded via the telemetry channels of a 56-year-old-female chronic Chagas disease patient. She underwent pacemaker implantation (DDDR mode) 8 years ago, due to advanced atrioventricular block, and generator change 4 months ago. She presented palpitations and presyncope with a duration up to 15 minutes, demonstrating telemetry ventricular tachycardia with a cycle frequency of 249 ms (241 beats per minute). There is ventriculoatrial conduction. The arrows show the pacemaker spikes. Patient was treated with furosemide, spironolactone, captopril, carvedilol, digoxin and amiodarone. By the echocardiogram, the ejection fraction was 0.27 without ventricular dyssynchrony, and the patient underwent implantation of a cardioverter-defibrillator, with control of symptoms.
We have focused on sycope to show that sycopes' prognosis depends on its cause. Investigation and risk stratification allow us to establish appropriate treatment for symptom control and prevention of sudden cardiac death. Prognosis of syncope in patients with Chagas heart disease is not a predictor of cardiac death, and is relevant to a joint assessment with other variables (3,19,20). In terms of a perspectives on the epidemic, large-scale vector control programs have been put in place since the 90's especially- spraying houses and roofs with insecticides to kill the insects, housing programs, and controls of blood and derivatives transfusion have been successful in containing transmission of Chagas disease in many countries of Latin America. However, the amazon deforestation causes the insects to fly to urban dwellings. Furthermore, a vast animal and human reservoir for the disease, with most those infected are unaware of their infection remain potential sources of transmission. Eradication without a vaccine seems difficult. In the meantime, globalisation of the disease seems inevitable (21).
1.Chagas disease World Health Organization. (American trypanosomiases), 2010. Jackson, Y., Castillo, S., Hammond, P., Besson, M., Brawand-Bron, A., Urzola, D., Gaspoz, J.-M. and Chappuis, F. (2012), Metabolic, mental health, behavioural and socioeconomic characteristics of migrants with Chagas disease in a non-endemic country. Tropical Medicine & International Health, 17: 595–603. doi: 10.1111/j.1365-3156.2012.02965.x 2.The globalization of Chagas disease Schmunis GA. . ISBT Science Series 2007; 2:6-11. 3.Chagas disease. Rassi Jr A, Rassi A, Marin-Neto JA. Lancet 2010; 375:1388-402. 4.I Diretriz Latino Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica Andrade JA, Marin-Neto JA, Paola AAV, Vilas-Boas F, Oliveira GMM, Bacal F, et al. Sociedade Brasileira de Cardiologia. Arq Bras Cardiol 2011; 97(2supl.3):1-47. 5. Guidelines for the diagnosis and management of syncope Task Force for the Diagnosis and Management of Syncope; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS), Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB, et al. (version 2009). Eur Heart J 2009; 30:2631-71. 6.Chagas' heart disease and the autonomic nervous system Dávila DF, Inglessis G, Mazzei de Dávila CA. Int J Cardiol 1998; 66:123-7. 7. Bradyarrhythmias in chagasic cardiomyopathy Zuloaga C. In Tentori MC, Segura EL, Hayes D (eds). Arrhythmia management in Chagas’ disease. New York: Futura Publishing Co. Inc., 2000, pp. 143-152. 8.Electrophysiologic findings in long-term asymptomatic chagasic individuals Pimenta J, Miranda M, Pereira CB. . Am Heart J 1983; 106:374-380. 9.Predictive value of clinical and electrophysiological variables in patients with chronic chagasic cardiomyopathy and nonsustained ventricular tachcardia. Silva RMFL, Távora MZP, Gondin FAA, Metha N, Hara VM, de Paola AAV. Arq Bras Cardiol 2000; 75:41-47. 10.Serial electrophysiological studies of the hearts excito conductor system in patients with chronic chagasic cardiopathy Valente N, Pimenta J, Paola AAV. Arq Bras Cardiol 2006; 86:19-25. 11.Sustained ventricular tachycardia in chronic chagasic myocarditis: electrophysiologic and pharmacologic characteristics. Mendoza I, Camargo J, Moleiro F, Castellanos A, Medina V, Gomes J, et al. Am J Cardiol 1986; 57:423-427. 12.Electrophysiologic-strutural correlations in chagasic aneurysms causing malignant arrhythmias. Milei J, Pesce R, Valero E, Muratore C, Beigelman R, Ferrans VJ. Int J Cardiol 1991; 32:65-74. 13. Mapeamento com radioisótopo do foco arritmogênico em pacientes com cardiopatia chagásica crônica e taquicardia ventricular sustentada De Paola AA, Balbão CE, Castiglioni ML, Barbieri A, Mendonça A, Netto OS, et al. Arq Bras Cardiol 1993; 60:373-376. 14.Características e identificação dos sítios de taquicardia ventricular de etiologia chagásica por mapeamento endocárdico. Távora MZ, Mehta N, Silva RM, Gondim FA, Hara VM, De Paola AA. Arq Bras Cardiol 1999; 72:451-462. 15.Endocardial and epicardial ablation guided by nonsurgical transthoracic epicardial mapping to treat recurrent ventricular tachycardia Sosa E, Scanavacca M, d’ Ávila A, Piccioni J, Sanchez O, Velarde JL, et al. J Cardiovasc Electrophysiol 1998; 9:229-239. 16.Ventricular tachycardia in Chagas’ disease: a comparison of clinical, angiographic, electrophysiologic and myocardial perfunsion disturbances between patients presenting with either sustained or nonsustained forms. Sarabanda AVL, Sosa E, Simões MV, Figueiredo GL, Pintya AO, Marin-Neto JA. Int J Cardiol 2005; 102:9-19. 17.Clinical and electrophysiologic features of syncope in chronic chagasic heart diasease. Martinelli M, Sosa E, Nishioka S, Scanavacca M, Bellotti G, Pileggi F. J Cardiovasc Electrophysiol 1994; 5:563-570. 18.The impact of syncope during clinical presentation of sustained ventricular tachycardia on total and cardiac mortality in patients with chronic chagasic heart disease. Leite LR, Fenelon G, Paes AT, de Paola AAV. Arq Bras Cardiol 2001; 77:446–52. 19.Predictors of mortality in patients with Chagas' cardiomyopathy and ventricular tachycardia not treated with implantable cardioverter-defibrillators Sarabanda AV, Marin-Neto JA. . Pacing Clin Electrophysiol 2011; 34:54-62. 20. Development and validation of a risk score for predicting death in Chagas' heart disease. Rassi Jr A, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. N Engl J Med 2006; 355:799-808. 21.Chagas cardiomyopathy: Europe is not spared!Roberto A. Guerri-Guttenberg, Daniel R. Grana, Giuseppe Ambrosio, and José Milei. Eur Heart J (2008) 29 (21): 2587-2591.
Rose Mary Ferreira Lisboa da Silva. MD, PhD, Associate Professor, Faculty of Medicine, Federal University of Minas Gerais, Brazil.
Author disclosures: None declared.
© 2017 European Society of Cardiology. All rights reserved